My smart ring said my glucose was "trending high" at 2:30 PM last Tuesday. I was sitting at my desk in East Austin, having just eaten a salad from Sweetgreen. A salad. The Dexcom G7 on my arm — the actual continuous glucose monitor, the medical-grade device with a needle and a transmitter and FDA approval — said my glucose was 94 mg/dL. Perfectly normal. The ring was wrong. Not slightly wrong. Dramatically wrong. And this is the central problem with non-invasive glucose monitoring in 2026.
I have been testing three devices that claim to track glucose trends without breaking skin: a smart ring, a smartwatch with optical sensors, and a fitness band with multi-wavelength PPG. I wore them simultaneously with a Dexcom G7 for 21 days. I logged every meal. I tracked every reading. I have 4,284 data points. And the conclusion is not flattering for the wearable industry.
Here is what the data says. The Circular Ring 2 announced a blood glucose trend analysis feature planned for late 2026, using PPG sensors and machine learning to analyze how light interacts with blood. Samsung has been developing cuffless blood pressure on Galaxy Watch since 2020. Multiple companies are pursuing similar approaches. The promise is transformative: continuous metabolic monitoring for hundreds of millions of users who would never wear a CGM patch. The reality is messier than the marketing.
Calculate your BMI instantly with visual category charts and history storage.
All data stays in your browser — we never see it.Day 3 of the experiment was the first red flag. I ate a controlled breakfast — 45g carbs, 20g protein, 12g fat — and measured glucose every 15 minutes for two hours. The Dexcom showed a predictable curve: baseline 88, peak at 45 minutes at 132, return to 95 by 90 minutes. The smart ring showed: baseline 92, peak at 30 minutes at 178, return to 88 by 60 minutes. The timing was wrong. The magnitude was wrong. The trend direction was wrong. The ring thought I was spiking earlier and higher than I actually was. If I had acted on that data — taken more insulin, eaten less, panicked — I would have caused harm.
I am not diabetic. I do not take insulin. But millions of pre-diabetetics and Type 2 diabetics will use these devices to make real decisions. A false high reading could trigger unnecessary medication. A false low reading could lead to dangerous hypoglycemia. The stakes are not theoretical. They are life and death. And the wearable industry is rushing to market with algorithms that have not been validated against clinical standards.
By day 7, I had identified three failure modes. First, motion artifact. The ring's PPG sensor is on the finger. Fingers move constantly. Typing. Gesturing. Holding coffee cups. Each motion introduces noise that the algorithm tries to correct, often over-correcting. During a 30-minute bike ride on the Butler Trail, the ring showed a glucose "crash" to 62 mg/dL. The Dexcom showed 112. The motion of gripping handlebars had confused the optical sensor.
Calculate your daily calorie needs with TDEE and activity level adjustments.
All data stays in your browser — we never see it.Second, skin temperature interference. The ring measures skin temperature to adjust its optical readings. But skin temperature changes with environment, not just metabolism. On day 12, I walked from my air-conditioned apartment to a coffee shop on East 6th Street. The outdoor temperature was 103°F. My skin temperature jumped 4.2°F. The ring's glucose algorithm interpreted this as a metabolic stress signal and showed a glucose spike to 165 mg/dL. The Dexcom showed 98. The ring had confused heat stress with carb absorption.
Third, calibration drift. The ring's glucose algorithm uses machine learning trained on population data. It assumes a baseline glucose distribution that may not match individual physiology. My fasting glucose runs 82-88 mg/dL. The ring's algorithm seemed calibrated for a population average of 95-100. It consistently overestimated my fasting glucose by 8-12 mg/dL. That is not a small error. That is the difference between normal and pre-diabetic in some guidelines.
I ran a Bland-Altman analysis on day 14. For the non-statisticians in the room, this is a method for comparing two measurement techniques. The mean difference between the ring and the Dexcom was 18.4 mg/dL. The limits of agreement — the range within which 95% of differences fall — were -34.2 to +71.0 mg/dL. That is a 105 mg/dL spread. For context, the FDA requires CGM devices to have mean absolute relative differences under 15% for most readings. The ring's performance was not even in the same stadium as FDA standards.
Estimate body fat percentage using the US Navy tape method and BMI-based formulas.
All data stays in your browser — we never see it.The smartwatch was slightly better but still unacceptable. Mean difference: 14.2 mg/dL. Limits of agreement: -28.1 to +56.5. The fitness band was the worst: mean difference 24.7 mg/dL, limits of agreement stretching to +89.3 mg/dL. None of these devices would pass clinical validation. None should be used for medical decision-making. And yet all three are marketed with language like "glucose trend insights" and "metabolic awareness" that implies medical utility without claiming it explicitly. It is regulatory arbitrage, and it is dangerous.
Here is the nuanced truth that the wearable industry does not want to hear. Non-invasive glucose monitoring is not impossible. It is just not ready. The physics of measuring glucose through skin with light is genuinely hard. Glucose does not have a strong optical signature in the near-infrared range. It is swamped by hemoglobin, water, and melanin signals. Machine learning can extract weak signals from noisy data, but only with massive training datasets and frequent clinical calibration. The current devices have neither. They have small training sets, population-level assumptions, and no individual calibration against blood draws.
I spoke with a biomedical engineer at UT Austin who works on optical biosensors. She told me — off the record, over tacos at Veracruz — that the field needs at least 3-5 more years of development before non-invasive glucose monitoring can approach CGM accuracy. The Circular Ring 2's planned glucose feature for late 2026? "Ambitious," she said, with the kind of diplomatic understatement that scientists use when they mean "probably not ready."
So what should you do with these devices? Use them for what they are: rough trend indicators, not medical tools. If your ring shows consistently elevated glucose trends over weeks, that might be a signal to talk to your doctor and get a real test. If it shows a single "high" reading after a salad, ignore it. The trend is the signal. The daily reading is noise. And the noise is currently very, very loud.
I will keep testing these devices as they improve. I will keep comparing them to the Dexcom. I will keep the spreadsheet open. Because the promise of needle-free glucose monitoring is worth pursuing. But the hype is ahead of the science. And in health tech, hype can hurt people. My ring said I was trending high. My Dexcom said I was fine. I believed the Dexcom. I ate the salad. And I am writing this article instead of calling an ambulance. That is the difference between a toy and a tool. We are not there yet. But I will keep running the numbers until we are.
